Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
- 26 Juin 2024 - 1 mn de lecture
The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.
26 Juin 2024
1 mn de lecture
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
26 Juin 2024
1 mn de lecture
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
26 Juin 2024
1 mn de lecture
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
26 Juin 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
26 Juin 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Follow-on Study
26 Juin 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Study
26 Juin 2024
1 mn de lecture
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
26 Juin 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Study
26 Juin 2024
1 mn de lecture
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
26 Juin 2024
1 mn de lecture